Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. BioVersys AG's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was CHF0.00 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.00 Mil.
BioVersys AG (XSWX:BIOV) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
BioVersys AG Selling, General, & Admin. Expense Related Terms
BioVersys AG Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Selling, General, & Admin. Expense Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Selling, General, & Admin. Expense
0.00
0.00
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Selling, General, & Admin. Expense
0.00
0.00
0.00
0.00
XSWX:BIOV vs VRTX, REGN, ALNY: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, BioVersys AG's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Selling, General, & Admin. Expense falls into.
BioVersys AG Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of CHF0.00 Mil mean?
BioVersys AG (XSWX:BIOV) has a Selling, General, & Admin. Expense of CHF0.00 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Selling, General, & Admin. Expense too high?
BioVersys AG's current Selling, General, & Admin. Expense is CHF0.00 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Selling, General, & Admin. Expense compare to VRTX and REGN?
BioVersys AG's Selling, General, & Admin. Expense of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on BioVersys AG and its competitors. BioVersys AG's current Selling, General, & Admin. Expense is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Selling, General, & Admin. Expense of CHF0.00 Mil. The current Selling, General, & Admin. Expense is CHF0.00 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Selling, General, & Admin. Expense is CHF0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 
